PALISADE BIO, INC. (PALI)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Research and development | 1,675 | 2,137 | ||
| General and administrative | 1,168 | 1,456 | ||
| Total operating expenses | 2,843 | 3,593 | ||
| Loss from operations | -2,843 | -3,593 | ||
| Other income, net | 61 | 112 | ||
| Interest expense | 2 | 6 | ||
| Total other income, net | 59 | 106 | ||
| Net loss | -2,784 | -3,487 | ||
| Basic net loss per common share | -0.58 | -2.32 | ||
| Diluted net loss per common share | -0.58 | -2.32 | ||
| Weighted average shares used in calculating basic loss per common share | 4,797,196 | 1,500,409 | ||
| Weighted average shares used in calculating diluted loss per common share | 4,797,196 | 1,500,409 | ||